Cellbxhealth Final Earnings Report

Cellbxhealth EPS Results

• Actual EPS: -GBX 5.51
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Cellbxhealth Revenue Results

• Actual Revenue: $1.35 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Cellbxhealth Announcement Details

• Quarter: Final
• Date: 6/22/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Cellbxhealth (LON:CLBX) plc is a precision CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and can be integrated with existing laboratory instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows. Commercial activities centre on (1) Product Sales: Accelerating Parsortix platform adoption and consumable sales through CROs and clinical lab partnerships. (2) Laboratory services: Clinical trial support and assay development (3) Lab Developed Tests (LDTs): Strategic partnerships combined with a focused in-house development programme. The product portfolio comprises the Parsortix® platform with associated consumables and assays. Laboratory services are delivered from CelLBxHealth's GCLP certified UK laboratory, providing bespoke clinical-trial support and assay development. For more information, visit https://cellbxhealth.com/.